Abstract: Provided are nutritional compositions containing dietary butyrate. Further disclosed are methods for reducing the incidence of obesity and metabolic syndrome in a target subject via administering the nutritional composition containing dietary butyrate to the target subject. Further provided are methods for improving adipose tissue functioning in a target subject.

Abstract: The present disclosure relates to nutritional supplement including a peptide component. The nutritional supplement further includes a source of long-chain polyunsaturated fatty acids and Lactobacillus rhamnosus GG. The disclosure further relates to methods of protecting against obesity and its related metabolic disorders and inflammatory diseases in a target subject by providing the nutritional supplement(s) disclosed herein to a target subject, which includes a pediatric subject.

Abstract: The present disclosure relates to nutritional supplement including a peptide component. The nutritional supplement further includes a source of long-chain polyunsaturated fatty acids and Lactobacillus rhamnosus GG. The disclosure further relates to methods of protecting against obesity and its related metabolic disorders and inflammatory diseases in a target subject by providing the nutritional supplement(s) disclosed herein to a target subject, which includes a pediatric subject.

Abstract: The present disclosure relates to nutritional supplement including a peptide component. The nutritional supplement further includes a source of long-chain polyunsaturated fatty acids and Lactobacillus rhamnosus GG. The disclosure further relates to methods of protecting against obesity and its related metabolic disorders and inflammatory diseases in a target subject by providing the nutritional supplement(s) disclosed herein to a target subject, which includes a pediatric subject.

Abstract: The present disclosure relates to nutritional supplement including a peptide component. The nutritional supplement further includes a source of long-chain polyunsaturated fatty acids and Lactobacillus rhamnosus GG. The disclosure further relates to methods of protecting against obesity and its related metabolic disorders and inflammatory diseases in a target subject by providing the nutritional supplement(s) disclosed herein to a target subject, which includes a pediatric subject.

Abstract: The present disclosure relates to nutritional supplement including a peptide component. The nutritional supplement further includes a source of long-chain polyunsaturated fatty acids and Lactobacillus rhamnosus GG. The disclosure further relates to methods of protecting against obesity and its related metabolic disorders and inflammatory diseases in a target subject by providing the nutritional supplement(s) disclosed herein to a target subject, which includes a pediatric subject.

Abstract: The present disclosure relates to nutritional supplement including a peptide component. The nutritional supplement further includes a source of long-chain polyunsaturated fatty acids and Lactobacillus rhamnosus GG. The disclosure further relates to methods of protecting against obesity and its related metabolic disorders and inflammatory diseases in a target subject by providing the nutritional supplement(s) disclosed herein to a target subject, which includes a pediatric subject.

Abstract: Provided are nutritional compositions comprising a combination of a probiotic, dietary butyrate and/or a component for stimulating butyrate production in the human gut. Further disclosed are methods of accelerating tolerance to cow's milk allergy in a pediatric subject by providing said nutritional compositions to a target subject.

Abstract: Provided are nutritional compositions containing inositol. Further disclosed are methods for promoting optimal and functional synaptic development in a target subject via administering the nutritional composition containing inositol to the target subject. Further provided are methods for promoting brain development and overall brain health and function in a target subject.

Abstract: Provided are nutritional compositions containing dietary butyrate. Further disclosed are methods for promoting and/or accelerating myelination in a target subject via administering the nutritional composition containing dietary butyrate to the target subject.

Abstract: The present disclosure is directed to methods for reducing the risk of developing or reducing the severity of a viral infection, bacterial infection, or viral and bacterial co-infection in a subject comprising administering to the subject a nutritional composition comprising an effective amount of a soluble mediator preparation derived from a late-exponential growth phase of a probiotic culture, such as Lactobacillus rhamnosus GG (LGG). The present disclosure, in certain embodiments, is directed to methods for reducing inflammation in a subject with a viral infection, bacterial infection, or viral and bacterial co-infections, comprising administering to the subject a nutritional composition comprising an effective amount of a soluble mediator preparation from a late-exponential growth phase of a probiotic culture, such as LGG.

Abstract: Provided are nutritional compositions containing dietary butyrate. Further disclosed are methods for reducing the incidence of obesity and metabolic syndrome in a target subject via administering the nutritional composition containing dietary butyrate to the target subject. Further provided are methods for improving adipose tissue functioning in a target subject.

Abstract: This disclosure relates to methods of inducing adipocyte browning, supporting metabolic flexibility, and/or reducing detrimental WAT deposition or reducing WAT dysfunction in a subject by administering extensively hydrolyzed casein and/or fractions thereof (“eHC”) to the subject, and/or by administering a long chain polyunsaturated fatty acid (e.g., docosahexaenoic acid and/or arachidonic acid) to the subject.

Abstract: The present disclosure is directed to methods for i) promoting gut regeneration, ii) promoting gut maturation and/or adaptation, iii) supporting gut barrier resistance and/or iv) protecting gut barrier function in a pediatric subject comprising administering to the pediatric subject a composition comprising an effective amount of a soluble mediator preparation derived from a late-exponential growth phase of a probiotic batch-cultivation process, such as Lactobacillus rhamnosus GG (LGG). The present methods advantageously provide the gut-protection benefits of LGG soluble mediators without introducing live bacterial culture to individuals with impaired gut barrier function. In some embodiments, the pediatric subject has impaired gut barrier function and/or short bowel syndrome.

Abstract: The present disclosure is directed to methods for i) promoting gut regeneration, ii) promoting gut maturation and/or adaptation, iii) supporting gut barrier resistance and/or iv) protecting gut barrier function in a pediatric subject comprising administering to the pediatric subject a composition comprising an effective amount of a soluble mediator preparation derived from a late-exponential growth phase of a probiotic batch-cultivation process, such as Lactobacillus rhamnosus GG (LGG). The present methods advantageously provide the gut-protection benefits of LGG soluble mediators without introducing live bacterial culture to individuals with impaired gut barrier function. In some embodiments, the pediatric subject has impaired gut barrier function and/or short bowel syndrome.

Abstract: Provided are nutritional compositions including a component for stimulating butyrate production in the human gut and/or dietary butyrate. Further disclosed are methods of reducing allergic reaction and promoting tolerance to cow's milk allergy in a pediatric subject by providing said nutritional compositions to a target subject.

Abstract: Provided are nutritional compositions comprising a combination of a probiotic, dietary butyrate and/or a component for stimulating butyrate production in the human gut. Further disclosed are methods of accelerating tolerance to cow's milk allergy in a pediatric subject by providing said nutritional compositions to a target subject.

Abstract: A composition comprising a culture supernatant from a late-exponential growth phase of a batch-cultivation process for a probiotic such as LGG, for use in the treatment or prevention of infection by a pathogen such as C. sakazakii.

Abstract: The present disclosure is directed to methods for i) promoting gut regeneration, ii) promoting gut maturation and/or adaptation, iii) supporting gut barrier resistance and/or iv) protecting gut barrier function in a pediatric subject comprising administering to the pediatric subject a composition comprising an effective amount of a soluble mediator preparation derived from a late-exponential growth phase of a probiotic batch-cultivation process, such as Lactobacillus rhamnosus GG (LGG). The present methods advantageously provide the gut-protection benefits of LGG soluble mediators without introducing live bacterial culture to individuals with impaired gut barrier function. In some embodiments, the pediatric subject has impaired gut barrier function and/or short bowel syndrome.

Abstract: A method for modulating a kinase by administering to a subject a nutritional composition comprising extensively hydrolyzed casein, extensively hydrolyzed casein fractions, or combinations thereof. A modulated kinase may be a kinase that regulates inflammatory signaling, immune tolerance, metabolic signaling, cell cycle and growth factor signaling. The nutritional composition may dose-dependently inhibit a range of serine, threonine and tyrosine kinases.